Ursa Health and Valtruis | June 28, 2022
Valtruis, a WCAS company, has entered a strategic partnership with Ursa Health, a healthcare data analytics company that brings a paradigm-breaking approach to how healthcare organizations use their data to learn, make decisions, and innovate
Valtruis portfolio companies Cricket Health and Wayspring are already experiencing quantifiable advances in their data analysis and management capabilities through both the Ursa Studio no-code analytics development platform and the unusually productive training, support, and consultative relationships they have formed with Ursa Health’s team of healthcare IT and data analytics experts.
“Building on the investments made in our first year – with Cricket Health, Wayspring, U.S. Medical Management (USMM) and Oncology Care Partners – we are moving quickly and strategically to realize our foundational commitment,” said Valtruis Managing Director Karey Witty. “That commitment is to accelerate the adoption of value-based care through investments in and collaboration with companies and entrepreneurs that share the vision, talent, and innovative strategies to make value-based care a reality. Ursa Health is one of those companies.”
“We bring scalable innovation to healthcare. Companies driving toward meaningful strategic innovation need their data to provide richer, more nuanced answers than healthcare as an industry has historically delivered – and they need these insights at the speed of business. Ursa Studio is a technology that unlocks a fresh approach to developing trusted information. On the technical level, the platform shifts IT team time from the labor of debugging code and managing data plumbing, opening up their capacity to answer additional business questions. On the human level, the platform enables rapid iteration and collaboration between the producers and consumers of analytics, bringing teams to a successful endpoint more quickly. As a result, organizations gain the self-service capacity to fill their information gaps and guide their innovations more efficiently and effectively.”
Ursa Health CEO and Co-Founder Robin Clarke, MD
Early-phase successes from Valtruis’ partner companies attest to the value, intelligence, and flexibility of the Ursa Health technology and analytics approach.
Adam Dunning, Chief Information and Analytics Officer at Wayspring, stated: “We needed a solution to fast-track the development of our SUD Home offering. Working with Ursa Studio, allowed us to accelerate the building of foundational data analytics structures. Our clients and staff will see notable returns as we continue to master the technology offering developed by Ursa Health.”
Valtruis, a WCAS company, provides a unique platform that invests in and partners with disruptive leaders whose mission is to align, and transform healthcare through what is truly value-based care. Founded on a commitment to accelerate meaningful change, Valtruis brings the functional expertise, access to capital, and an expansive network that advance our partners’ evolution from early-stage development to industry-leading enterprises. Together, Valtruis and its partner companies will break through the systemic barriers in the healthcare industry to reduce costs, expand access, increase quality, and radically improve the patient experience.
About Ursa Health
Ursa Health is transforming analytics so innovators can transform healthcare. Our analytics development platform, Ursa Studio, combines no-code technology with healthcare-specific content, enabling health plans, providers, digital health companies, and others to take a Buy Your Build™ approach to their analytics infrastructure. With the structured adaptability of Ursa Studio, organizations can make full use of their rich data resources to accelerate growth.
Camelot | June 06, 2022
After a rigorous agency selection process, Camelot Strategic Marketing & Media has been chosen as media buying and planning agency for healthcare technology company Cue Health (“Cue”) as it aims to pioneer the digital transformation of healthcare, beginning with diagnostics.
The scope of Camelot’s work for Cue includes integrated media planning and buying across Cue’s growing diagnostic platform, aimed at providing better patient outcomes by delivering on the promise of timely, informed, and connected healthcare.
“There is no question that Cue Health is on the leading edge of healthcare technology. We’re thrilled to align our passion for innovation, deep data and analytics, and creative digital media and marketing strategy to help drive their success into the future.”
Sam Bloom, CEO of Camelot Strategic Marketing & Media
Cue empowers people to live their healthiest lives by giving individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. Cue launched the first FDA-authorized COVID-19 molecular test for at-home and over-the-counter use as well as professional point-of-care use. Outside the U.S., Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, regulatory approval from India's Central Drugs Standard Control Organization, and PSAR authorization from Singapore’s Health Sciences Authority.
The company is developing future care offerings across several categories, including respiratory health, sexual health, cardiac and metabolic health, women's health, men's health, and chronic disease management.
Within the health and wellness space, Camelot also works with Baylor Scott & White Health, the largest not-for-profit healthcare system in Texas and one of the largest in the U.S., and Glo, a digital health platform and app providing live and on-demand yoga, meditation, Pilates and fitness classes.
Celebrating 40 years in the media and marketing industry, Dallas-based Camelot Strategic Marketing & Media, is a fact-based, bottom-up, independent agency with 150 employees in cities across the U.S. – including Dallas, New York, Los Angeles and Baltimore. We partner with a select group of the world’s biggest brands – from TurboTax to Whole Foods to Michaels – to provide media-agnostic, transparent, insight-driven media and marketing strategy and execution.
UPS | August 08, 2022
UPS announced plans to acquire Bomi Group, an industry-leading multinational healthcare logistics provider. The transaction will add temperature-controlled facilities in 14 countries and nearly 3,000 highly-skilled Bomi Group team members to the UPS Healthcare network in Europe and Latin America.
“As a leading global healthcare logistics company, Bomi enhances our portfolio of services and accelerates our journey to become the number one provider of complex healthcare logistics. UPS Healthcare and Bomi Group employees share similar values and our cultures are firmly rooted in a relentless focus on quality. The combination of our two teams will significantly improve our healthcare customers’ ability to continue to develop and deliver life-saving innovations.”
EVP and President of UPS International, Healthcare and Supply Chain Solutions Kate Gutmann
Since 1985, Bomi Group has provided high value-added services for the Medtech and Pharma sectors with a customized and tailored approach. It is a quality-focused company devoted to healthcare that has built solid and long-lasting business relationships with more than 150 multinational customers worldwide.
Key Bomi Group leaders, including CEO Marco Ruini, will continue in their roles to provide seamless service to Bomi Group customers after the transaction closes. Bomi Group’s employees will also continue to play vital roles in the combined organization.
“With over 35 years in the healthcare logistics industry, our team has developed best-in-class services designed to meet and exceed the needs of our medical technology and pharmaceutical customers,” said Ruini. “Joining the UPS team will expand those capabilities and create an even more integrated and powerful global network for our customers.”
The acquisition will add more than 350 temperature-controlled vehicles and four million square feet to the UPS Healthcare global footprint, offering customers access to faster shipping times, greater production flexibility, and offerings to help them attract new business. The acquisition will play a key role in the delivery of next-generation pharmaceutical and biologic treatments that increasingly require time-critical and temperature-sensitive logistics.
“We are focused on building healthcare logistics capabilities and services that allow our customers to deliver the newest healthcare innovations,” said UPS Healthcare President Wes Wheeler. “We are excited to combine Bomi’s talent, expertise and capabilities with UPS Healthcare – together, we will provide unmatched solutions to our customers, powered by UPS’s integrated, global smart logistics network.”
The acquisition of Bomi is part of UPS Healthcare’s continued expansion of its network and services to meet growing demand – including Bomi, UPS Healthcare has doubled its global footprint since 2020. Recent expansions include newly constructed and soon-to-be-opened dedicated state-of-the-art healthcare logistics facilities in Germany and Australia, and expanded campuses in Hungary and the Netherlands.
UPS Healthcare also recently enhanced UPS Premier, a technology-led service that can prioritize and track critical shipments within 10 feet of their location anywhere in UPS’s global network. UPS Premier brings worldwide visibility, control, reliability and product recovery capabilities to UPS Healthcare customers.
These expansions and new services meet the complex and varied needs of UPS Healthcare’s customers, helping them turn logistics into a competitive advantage.
The transaction is expected to close by the end of the year, subject to customary regulatory review and approval. The value and terms of the transaction are not being disclosed at this time. J.P. Morgan Securities LLC served as the financial advisor to UPS.
UPS is one of the world’s largest companies, with 2021 revenue of $97.3 billion, and provides a broad range of integrated logistics solutions for customers in more than 220 countries and territories. Focused on its purpose statement, “Moving our world forward by delivering what matters,” the company’s more than 500,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. UPS is committed to reducing its impact on the environment and supporting the communities we serve around the world. UPS also takes an unwavering stance in support of diversity, equity and inclusion.
About UPS Healthcare
UPS Healthcare delivers unparalleled healthcare logistics expertise to its customers around the world. UPS Healthcare has 11+ million square feet of cGMP and GDP-compliant healthcare distribution space globally. Services include inventory management, cold chain packaging and shipping, storage and fulfillment of medical devices, and lab and clinical trial logistics. UPS Healthcare's global infrastructure, its UPS® Premier visibility service, its track and trace technology, and its global quality system are well-suited to meet today's complex logistics demands for the pharmaceutical, medical device, and laboratory diagnostic industries.
About Bomi Group
BOMI GROUP is a leading Italian multinational company in the field of integrated logistics serving the Healthcare sector. Bomi is the logistics partner of more than 150 customers worldwide, including major players in the medical device, in vitro diagnostics, biomedical and pharmaceutical sectors. The Group is present through its subsidiaries and affiliates in 14 countries worldwide, with a particular focus on Europe and South America, employs over 3,000 people and has its own fleet of vehicles for daily deliveries to hospitals, clinics, laboratories, pharmacies and home patients.
FUTURE OF HEALTHCARE
Dalrada Corporation | June 09, 2022
Dalrada Corporation announced that it had acquired the pharmacy, Watson Rx Solutions, Inc. The move highlights Dalrada’s aggressive growth plans within the healthcare sector and paves the way for a total end-to-end total healthcare solution.
Adding the 10-year-old pharmacy to Dalrada Health’s comprehensive model expands the subsidiary’s synergies with potential opportunities across its products and services portfolio and offers another solution to meet patient requirements.
Dalrada envisions a comprehensive healthcare solution for all Dalrada Health clients with unique offerings that will now include: a pharmacy to facilitate prescription processing, physicians and clinicians at treatment clinics, expanding into telemedicine, engagement of Dalrada-owned testing facilities and laboratories, and utilization of Company-specific technologies to facilitate immediate growth of the business.
“Watson Rx has a long history of providing excellent pharmacy services. This acquisition allows Dalrada to expand its healthcare footprint and continue to build a total health management solution on an already successful turnkey operation. As a result, the Company will be able to successfully address the health needs of even more patients.”
CEO and Founder, Brian Bonar
Through comprehensive prescription management, education, nursing, and total health management, Watson Rx Solutions' leadership team holds more than six decades of combined experience in various complex pharmacy disease states and retail services, always putting patients first.
Dalrada plans on entering the pharmaceutical space with an accelerated strategic plan to leverage the Company’s existing capabilities. Research reveals that the U.S. online and mail-order sales of drugs, health, and beauty aids were valued at 75.5 billion USD in 2020. Additionally,
E-commerce pharmaceutical sales and beauty aids increased from 51.7 billion USD the year prior.
Online, E-commerce, and mail-order sales increased from around 31 to 38 percent during the same period.
Pharmacy and drug store sales reached 300 billion USD in 2020, with over-the-counter (OTC) medication accounting for over 36 billion USD in sales during the same year, the highest-selling year to date for the OTC segment.
Dalrada and its subsidiaries provide value by making timely and impactful products and services available within health, technology, and clean energy markets.
Dalrada Corporation drives innovation that positively impacts people, businesses, and the planet. With subsidiaries that are firmly positioned in the world’s top three-growing industries of healthcare, clean energy, and technology, Dalrada creates solutions that are sustainable, affordable, and accessible.
The company works continually to produce disruptive products and services that accelerate positive change for current and future generations. Dalrada’s global solutions directly address climate change, post-pandemic gaps in the healthcare industry, and technology solutions for a new era of human behavior and interaction, ensuring a bright future for the world around us.